Besivance
These highlights do not include all the information needed to use BESIVANCE safely and effectively. See full prescribing information for BESIVANCE. BESIVANCE (besifloxacin ophthalmic suspension), for topical ophthalmic useInitial U.S. Approval: 2009
Approved
Approval ID
a3e6d688-7e5e-4ca3-b27e-79756c322a32
Product Type
HUMAN PRESCRIPTION DRUG LABEL
Effective Date
Feb 2, 2022
Manufacturers
FDA
Bausch & Lomb Incorporated
DUNS: 196603781
Products 1
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
Besifloxacin
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
NDC Product Code24208-446
Application NumberNDA022308
Product Classification
M
Marketing Category
C73594
G
Generic Name
Besifloxacin
Product Specifications
Route of AdministrationOPHTHALMIC
Effective DateFebruary 2, 2022
FDA Product Classification
INGREDIENTS (9)
BENZALKONIUM CHLORIDEInactive
Code: F5UM2KM3W7
Classification: IACT
POLYCARBOPHILInactive
Code: W25LM17A4W
Classification: IACT
BESIFLOXACINActive
Quantity: 6 mg in 1 mL
Code: BFE2NBZ7NX
Classification: ACTIB
MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT
EDETATE DISODIUMInactive
Code: 7FLD91C86K
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8X
Classification: IACT
POLOXAMER 407Inactive
Code: TUF2IVW3M2
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT